Richard Daneman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Richard Daneman has a total of 262 co-authors. Here are the top co-authors by number of shared publications:
- Caterina P. Profaci
Departments of Pharmacology and Neurosciences, University of California, San Diego, La Jolla, CA, USA
5 shared publications - Allison Soung
Department of Neuroscience Genentech Inc South San Francisco California USA
3 shared publications - Benjamin D. Gastfriend
Department of Pharmacology, University of California, San Diego
3 shared publications Cayce E. Dorrier
Departments of Pharmacology and Neurosciences, University of California, San Diego, La Jolla, CA, USA
3 shared publications- Geoffrey Aaron Weiner
Departments of Pharmacology and Neurosciences, University of California, San Diego, La Jolla, USA
3 shared publications - Lucija Pintarić
Departments of Pharmacology and Neurosciences, University of California, San Diego, La Jolla, USA
3 shared publications
Latest Publications
- Open Access
- 19 March 2026
- Published by Springer Nature in Molecular Brain
- Vol. 19 (1)
Central nervous system pericytes express soluble ST2 in inflammation and injury
Brain pericytes are mediators of neuroinflammation, as evidenced in vitro, in animal models and humans. We and others have identified the platelet-derived growth factor (PDGF)-BB -PDGF receptor beta (PDGFRB) pathway as a key modulator of inflammatory cues in human brain pericytes. We investigate the receptor for interkeukin-33 (IL-33), interkeukin-1 receptor-like 1 (IL1RL1; also known as ST2) as a highly upregulated transcript in response to PDGF-BB stimulation in pericyte cultures. We show that pericytes express transcripts for both the membrane bound form of the receptor (ST2L) and the soluble form (sST2) that acts as a decoy and blocks IL-33 signalling. Human brain pericytes secrete sST2 in response to PDGF-BB, but also to transforming growth factor alpha (TGF) alpha and interleukin-4 (IL-4), although they are unresponsive to IL-33 treatment. We also examine pericyte expression of both IL1RL1 transcripts using RNAscope in two different in vivo models of neuroinflammation, experimental autoimmune encephalitis (EAE) and photothrombotic stroke. We present data showing that in rodents pericytes increase transcript expression predominantly for soluble IL1RL1 in inflammatory and stroke models. Our results highlight a novel expression pattern of the soluble and membrane bound forms of the IL-33 receptor in vitro and in combination with our observations in vivo suggest that cerebrovascular pericytes may negatively regulate IL-33 signalling following injury or inflammatory insults to the brain.
- 19 March 2026
- Published by Springer Nature in Molecular Brain
- Vol. 19 (1)
Open AccessCentral nervous system pericytes express soluble ST2 in inflammation and injury
Brain pericytes are mediators of neuroinflammation, as evidenced in vitro, in animal models and humans. We and others have identified the platelet-derived growth factor (PDGF)-BB -PDGF receptor beta (PDGFRB) pathway as a key modulator of inflammatory cues in human brain pericytes. We investigate the receptor for interkeukin-33 (IL-33), interkeukin-1 receptor-like 1 (IL1RL1; also known as ST2) as a highly upregulated transcript in response to PDGF-BB stimulation in pericyte cultures. We show that pericytes express transcripts for both the membrane bound form of the receptor (ST2L) and the soluble form (sST2) that acts as a decoy and blocks IL-33 signalling. Human brain pericytes secrete sST2 in response to PDGF-BB, but also to transforming growth factor alpha (TGF) alpha and interleukin-4 (IL-4), although they are unresponsive to IL-33 treatment. We also examine pericyte expression of both IL1RL1 transcripts using RNAscope in two different in vivo models of neuroinflammation, experimental autoimmune encephalitis (EAE) and photothrombotic stroke. We present data showing that in rodents pericytes increase transcript expression predominantly for soluble IL1RL1 in inflammatory and stroke models. Our results highlight a novel expression pattern of the soluble and membrane bound forms of the IL-33 receptor in vitro and in combination with our observations in vivo suggest that cerebrovascular pericytes may negatively regulate IL-33 signalling following injury or inflammatory insults to the brain.
- Open Access
Forward Programming Identifies Inducers of Blood-Brain Barrier Properties in Human Pluripotent Stem Cell-Derived Endothelial Cells
Brain microvascular endothelial cells (BMECs) forming the blood-brain barrier (BBB) maintain brain homeostasis through specialized properties such as tight junctions, efflux transporters, and low levels of transcytosis. However, mechanisms governing induction of BBB properties during development remain poorly understood. We mined single-cell RNA sequencing datasets to identify transcription factors (TFs) critical for BBB development. Forty-four TFs were overexpressed in human pluripotent stem cell-derived endothelial cells cultured in the presence of the Wnt pathway agonist CHIR99021 to identify TFs capable of directing acquisition of BBB properties via forward programming. Individual TFs, including KLF2 , KLF4 , FOXF1 , FOXF2 , ZIC2 , ZIC3 , NR4A1 , NR4A2 , FOXC1 , and FOXQ1 , induced distinct BBB-like gene expression patterns. Combinations of these TFs induced many canonical BBB genes, yielding ECs with reduced endocytosis, increased efflux activity, and improved barrier function. The resultant forward programmed CNS-like ECs (fpCECs) offer promising tools for modeling human BBB development and neurovascular disease and for drug screening.
Open AccessForward Programming Identifies Inducers of Blood-Brain Barrier Properties in Human Pluripotent Stem Cell-Derived Endothelial Cells
Brain microvascular endothelial cells (BMECs) forming the blood-brain barrier (BBB) maintain brain homeostasis through specialized properties such as tight junctions, efflux transporters, and low levels of transcytosis. However, mechanisms governing induction of BBB properties during development remain poorly understood. We mined single-cell RNA sequencing datasets to identify transcription factors (TFs) critical for BBB development. Forty-four TFs were overexpressed in human pluripotent stem cell-derived endothelial cells cultured in the presence of the Wnt pathway agonist CHIR99021 to identify TFs capable of directing acquisition of BBB properties via forward programming. Individual TFs, including KLF2 , KLF4 , FOXF1 , FOXF2 , ZIC2 , ZIC3 , NR4A1 , NR4A2 , FOXC1 , and FOXQ1 , induced distinct BBB-like gene expression patterns. Combinations of these TFs induced many canonical BBB genes, yielding ECs with reduced endocytosis, increased efflux activity, and improved barrier function. The resultant forward programmed CNS-like ECs (fpCECs) offer promising tools for modeling human BBB development and neurovascular disease and for drug screening.
- Top Cited PapersOpen Access
- 15 January 2026
- Published by The Company of Biologists in Development
- Vol. 153 (2)
Development of the blood–brain barrier
The blood–brain barrier (BBB) is a term used to describe the specialized properties of vasculature in the central nervous system (CNS) that regulate the exchange of ions, molecules and cells, thereby maintaining CNS homeostasis. These BBB properties are largely possessed by vascular endothelial cells, which exhibit molecular specializations that distinguish them from endothelial cells in other organs. BBB development – orchestrated by complex interactions between endothelial cells, neural progenitor cells, pericytes, astrocytes, neurons and other cell types that form the neurovascular unit – is initiated concurrently with CNS angiogenesis and continues during expansion and maturation of the vasculature. Importantly, the Wnt/β-catenin signaling pathway plays a central role in barriergenesis, the initial acquisition of BBB phenotype in endothelial cells. In this Review, we summarize current understanding of BBB development, including timing and underlying cellular and molecular mechanisms. We also discuss established and emerging techniques for studying BBB development and highlight important unanswered questions in the field.
- 15 January 2026
- Published by The Company of Biologists in Development
- Vol. 153 (2)
Top Cited PapersOpen AccessDevelopment of the blood–brain barrier
The blood–brain barrier (BBB) is a term used to describe the specialized properties of vasculature in the central nervous system (CNS) that regulate the exchange of ions, molecules and cells, thereby maintaining CNS homeostasis. These BBB properties are largely possessed by vascular endothelial cells, which exhibit molecular specializations that distinguish them from endothelial cells in other organs. BBB development – orchestrated by complex interactions between endothelial cells, neural progenitor cells, pericytes, astrocytes, neurons and other cell types that form the neurovascular unit – is initiated concurrently with CNS angiogenesis and continues during expansion and maturation of the vasculature. Importantly, the Wnt/β-catenin signaling pathway plays a central role in barriergenesis, the initial acquisition of BBB phenotype in endothelial cells. In this Review, we summarize current understanding of BBB development, including timing and underlying cellular and molecular mechanisms. We also discuss established and emerging techniques for studying BBB development and highlight important unanswered questions in the field.
- Open Access
- 30 December 2025
- Published by Springer Nature in Research Square
Mannosamine preserves blood brain barrier integrity and promotes angiogenesis in a stroke model
Cerebral ischemia remains a major global health challenge, contributing significantly to long-term disability and mortality, with limited therapeutic options currently available. This study explores the therapeutic potential of Mannosamine (ManN), an hexosamine previously shown to be a mitogen for endothelial cells (ECs), in the context of cerebral ischemic injury. Using a transient middle cerebral artery occlusion (tMCAO) mouse model, we assessed the effects of ManN administration on ischemic brain damage. Mice receiving ManN exhibited significantly smaller infarct volumes, as measured by magnetic resonance imaging (MRI), and reduced blood–brain barrier (BBB) permeability compared to controls. ManN treatment enhanced pericyte coverage, improved EC survival, and increased vascular density in the ischemic brain regions. Our analyses revealed attenuation of ischemia-induced structural abnormalities, including reduced vacuolation, cellular shrinkage, and nuclear condensation. To elucidate the underlying mechanisms, in vitro experiments with brain endothelial cells (bEND.3) demonstrated that ManN treatment promoted GSK3β phosphorylation and facilitated nuclear accumulation of β-catenin. This activation of the Wnt/β-catenin pathway led to upregulation of key target genes such as LEF1 , TCF7 , AXIN2 , and APCDD1 . Enhanced interaction of β-catenin with LEF1/TCF7 was associated with increased expression of tight junction proteins and transcytosis inhibitors, contributing to BBB stabilization and angiogenic support. Collectively, these findings highlight the ability of ManN to activate endothelial Wnt/β-catenin signaling, thereby preserving BBB integrity and promoting angiogenesis, suggesting its promise as a novel therapeutic strategy for cerebral ischemia.
- 30 December 2025
- Published by Springer Nature in Research Square
Open AccessMannosamine preserves blood brain barrier integrity and promotes angiogenesis in a stroke model
Cerebral ischemia remains a major global health challenge, contributing significantly to long-term disability and mortality, with limited therapeutic options currently available. This study explores the therapeutic potential of Mannosamine (ManN), an hexosamine previously shown to be a mitogen for endothelial cells (ECs), in the context of cerebral ischemic injury. Using a transient middle cerebral artery occlusion (tMCAO) mouse model, we assessed the effects of ManN administration on ischemic brain damage. Mice receiving ManN exhibited significantly smaller infarct volumes, as measured by magnetic resonance imaging (MRI), and reduced blood–brain barrier (BBB) permeability compared to controls. ManN treatment enhanced pericyte coverage, improved EC survival, and increased vascular density in the ischemic brain regions. Our analyses revealed attenuation of ischemia-induced structural abnormalities, including reduced vacuolation, cellular shrinkage, and nuclear condensation. To elucidate the underlying mechanisms, in vitro experiments with brain endothelial cells (bEND.3) demonstrated that ManN treatment promoted GSK3β phosphorylation and facilitated nuclear accumulation of β-catenin. This activation of the Wnt/β-catenin pathway led to upregulation of key target genes such as LEF1 , TCF7 , AXIN2 , and APCDD1 . Enhanced interaction of β-catenin with LEF1/TCF7 was associated with increased expression of tight junction proteins and transcytosis inhibitors, contributing to BBB stabilization and angiogenic support. Collectively, these findings highlight the ability of ManN to activate endothelial Wnt/β-catenin signaling, thereby preserving BBB integrity and promoting angiogenesis, suggesting its promise as a novel therapeutic strategy for cerebral ischemia.
- Open Access
- 8 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 7332
Regional heterogeneity of the blood-brain barrier
The blood-brain barrier (BBB), formed by specialized endothelial cells (ECs), regulates the extracellular composition of the central nervous system (CNS). Little is known about whether there are regional specializations of the BBB that may control the function of specific neural circuits. We use single cell RNA-seq to characterize ECs from nine CNS regions in male mice: cortex, hippocampus, cerebellum, spinal cord, striatum, thalamus, hypothalamus, midbrain, and medulla/pons. Although there is a core BBB transcriptional profile, there are significant regional specializations. Stra6, a retinoid transporter, is highly enriched in the BBB of the nucleus accumbens shell (ShNAc) and ventral cochlear nucleus, and is controlled by dietary vitamin A, through endothelial RARƔ. EC Stra6 regulates the deposition of retinoids specifically in the ShNAc and cochlear nucleus, and is required for the function of the ShNAc, in a retinoid-dependent manner. Thus regional specializations of the BBB can regulate the function of local brain regions.
- 8 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 7332
Open AccessRegional heterogeneity of the blood-brain barrier
The blood-brain barrier (BBB), formed by specialized endothelial cells (ECs), regulates the extracellular composition of the central nervous system (CNS). Little is known about whether there are regional specializations of the BBB that may control the function of specific neural circuits. We use single cell RNA-seq to characterize ECs from nine CNS regions in male mice: cortex, hippocampus, cerebellum, spinal cord, striatum, thalamus, hypothalamus, midbrain, and medulla/pons. Although there is a core BBB transcriptional profile, there are significant regional specializations. Stra6, a retinoid transporter, is highly enriched in the BBB of the nucleus accumbens shell (ShNAc) and ventral cochlear nucleus, and is controlled by dietary vitamin A, through endothelial RARƔ. EC Stra6 regulates the deposition of retinoids specifically in the ShNAc and cochlear nucleus, and is required for the function of the ShNAc, in a retinoid-dependent manner. Thus regional specializations of the BBB can regulate the function of local brain regions.
- Open Access
- 8 November 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (21)
Microglia drive diurnal variation in susceptibility to inflammatory blood-brain barrier breakdown
The blood-brain barrier (BBB) is critical for maintaining brain homeostasis but is susceptible to inflammatory dysfunction. While transporter-dependent efflux of some lipophilic substrates across the BBB shows circadian variation due to rhythmic transporter expression, basal transporter–independent permeability and leakage is nonrhythmic. Whether daily timing influences BBB permeability in response to inflammation is unknown. Here, we induced systemic inflammation through repeated LPS injections either in the morning (ZT1) or evening (ZT13) under standard lighting conditions; we then examined BBB permeability to a polar molecule that is not a transporter substrate, sodium fluorescein. We observed clear diurnal variation in inflammatory BBB permeability, with a striking increase in paracellular leak across the BBB specifically following evening LPS injection. Evening LPS led to persisting glia activation as well as inflammation in the brain that was not observed in the periphery. The exaggerated evening neuroinflammation and BBB disruption were suppressed by microglial depletion or through keeping mice in constant darkness. Our data show that diurnal rhythms in microglial inflammatory responses to LPS drive daily variability in BBB breakdown and reveal time of day as a key regulator of inflammatory BBB disruption.
- 8 November 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (21)
Open AccessMicroglia drive diurnal variation in susceptibility to inflammatory blood-brain barrier breakdown
The blood-brain barrier (BBB) is critical for maintaining brain homeostasis but is susceptible to inflammatory dysfunction. While transporter-dependent efflux of some lipophilic substrates across the BBB shows circadian variation due to rhythmic transporter expression, basal transporter–independent permeability and leakage is nonrhythmic. Whether daily timing influences BBB permeability in response to inflammation is unknown. Here, we induced systemic inflammation through repeated LPS injections either in the morning (ZT1) or evening (ZT13) under standard lighting conditions; we then examined BBB permeability to a polar molecule that is not a transporter substrate, sodium fluorescein. We observed clear diurnal variation in inflammatory BBB permeability, with a striking increase in paracellular leak across the BBB specifically following evening LPS injection. Evening LPS led to persisting glia activation as well as inflammation in the brain that was not observed in the periphery. The exaggerated evening neuroinflammation and BBB disruption were suppressed by microglial depletion or through keeping mice in constant darkness. Our data show that diurnal rhythms in microglial inflammatory responses to LPS drive daily variability in BBB breakdown and reveal time of day as a key regulator of inflammatory BBB disruption.
- Open Access
- 2 February 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (5) , eadi1737
Notch3 directs differentiation of brain mural cells from human pluripotent stem cell–derived neural crest
Brain mural cells regulate development and function of the blood-brain barrier and control blood flow. Existing in vitro models of human brain mural cells have low expression of key mural cell genes, including NOTCH3 . Thus, we asked whether activation of Notch3 signaling in hPSC-derived neural crest could direct the differentiation of brain mural cells with an improved transcriptional profile. Overexpression of the Notch3 intracellular domain (N3ICD) induced expression of mural cell markers PDGFRβ, TBX2, FOXS1 , KCNJ8 , SLC6A12 , and endogenous Notch3. The resulting N3ICD-derived brain mural cells produced extracellular matrix, self-assembled with endothelial cells, and had functional K ATP channels. ChIP-seq revealed that Notch3 serves as a direct input to relatively few genes in the context of this differentiation process. Our work demonstrates that activation of Notch3 signaling is sufficient to direct the differentiation of neural crest to mural cells and establishes a developmentally relevant differentiation protocol.
- 2 February 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (5) , eadi1737
Open AccessNotch3 directs differentiation of brain mural cells from human pluripotent stem cell–derived neural crest
Brain mural cells regulate development and function of the blood-brain barrier and control blood flow. Existing in vitro models of human brain mural cells have low expression of key mural cell genes, including NOTCH3 . Thus, we asked whether activation of Notch3 signaling in hPSC-derived neural crest could direct the differentiation of brain mural cells with an improved transcriptional profile. Overexpression of the Notch3 intracellular domain (N3ICD) induced expression of mural cell markers PDGFRβ, TBX2, FOXS1 , KCNJ8 , SLC6A12 , and endogenous Notch3. The resulting N3ICD-derived brain mural cells produced extracellular matrix, self-assembled with endothelial cells, and had functional K ATP channels. ChIP-seq revealed that Notch3 serves as a direct input to relatively few genes in the context of this differentiation process. Our work demonstrates that activation of Notch3 signaling is sufficient to direct the differentiation of neural crest to mural cells and establishes a developmentally relevant differentiation protocol.
- Open Access
- 25 January 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (2)
Dural mural cells paint an anti-inflammatory picture
Mural cells directly contact macrophages in the dural layer of the meninges to suppress pro-inflammatory phenotypes, including antigen presentation and lymphocyte differentiation. These mechanisms represent new targets for modulating CNS immune surveillance and pathological inflammation (Min et al. 2024. J. Exp. Med.https://doi.org/10.1084/jem.20230326).
- 25 January 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (2)
Open AccessDural mural cells paint an anti-inflammatory picture
Mural cells directly contact macrophages in the dural layer of the meninges to suppress pro-inflammatory phenotypes, including antigen presentation and lymphocyte differentiation. These mechanisms represent new targets for modulating CNS immune surveillance and pathological inflammation (Min et al. 2024. J. Exp. Med.https://doi.org/10.1084/jem.20230326).
- Open Access
- 1 May 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (9)
Epsilon toxin–producing Clostridium perfringens colonize the multiple sclerosis gut microbiome overcoming CNS immune privilege
Multiple sclerosis (MS) is a complex disease of the CNS thought to require an environmental trigger. Gut dysbiosis is common in MS, but specific causative species are unknown. To address this knowledge gap, we used sensitive and quantitative PCR detection to show that people with MS were more likely to harbor and show a greater abundance of epsilon toxin–producing (ETX-producing) strains of C. perfringens within their gut microbiomes compared with individuals who are healthy controls (HCs). Isolates derived from patients with MS produced functional ETX and had a genetic architecture typical of highly conjugative plasmids. In the active immunization model of experimental autoimmune encephalomyelitis (EAE), where pertussis toxin (PTX) is used to overcome CNS immune privilege, ETX can substitute for PTX. In contrast to PTX-induced EAE, where inflammatory demyelination is largely restricted to the spinal cord, ETX-induced EAE caused demyelination in the corpus callosum, thalamus, cerebellum, brainstem, and spinal cord, more akin to the neuroanatomical lesion distribution seen in MS. CNS endothelial cell transcriptional profiles revealed ETX-induced genes that are known to play a role in overcoming CNS immune privilege. Together, these findings suggest that ETX-producing C. perfringens strains are biologically plausible pathogens in MS that trigger inflammatory demyelination in the context of circulating myelin autoreactive lymphocytes.
- 1 May 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (9)
Open AccessEpsilon toxin–producing Clostridium perfringens colonize the multiple sclerosis gut microbiome overcoming CNS immune privilege
Multiple sclerosis (MS) is a complex disease of the CNS thought to require an environmental trigger. Gut dysbiosis is common in MS, but specific causative species are unknown. To address this knowledge gap, we used sensitive and quantitative PCR detection to show that people with MS were more likely to harbor and show a greater abundance of epsilon toxin–producing (ETX-producing) strains of C. perfringens within their gut microbiomes compared with individuals who are healthy controls (HCs). Isolates derived from patients with MS produced functional ETX and had a genetic architecture typical of highly conjugative plasmids. In the active immunization model of experimental autoimmune encephalomyelitis (EAE), where pertussis toxin (PTX) is used to overcome CNS immune privilege, ETX can substitute for PTX. In contrast to PTX-induced EAE, where inflammatory demyelination is largely restricted to the spinal cord, ETX-induced EAE caused demyelination in the corpus callosum, thalamus, cerebellum, brainstem, and spinal cord, more akin to the neuroanatomical lesion distribution seen in MS. CNS endothelial cell transcriptional profiles revealed ETX-induced genes that are known to play a role in overcoming CNS immune privilege. Together, these findings suggest that ETX-producing C. perfringens strains are biologically plausible pathogens in MS that trigger inflammatory demyelination in the context of circulating myelin autoreactive lymphocytes.
- 28 October 2022
- Published by H1 Connect
Faculty Opinions recommendation of Myelinating Schwann cells and Netrin-1 control intra-nervous vascularization of the developing mouse sciatic nerve.
For the first time, researchers in this manuscript detail the process of peripheral nerve vascularization in early development, finding that vessels do not invade the nerve space until close to birth. They also show strong links between myelin maturation and vascular health as well as evidence for a novel vessel-guiding molecule in the peripheral nervous system. Overall this paper highlights important biological processes in regards to peripheral nerve development.
- 28 October 2022
- Published by H1 Connect
Faculty Opinions recommendation of Myelinating Schwann cells and Netrin-1 control intra-nervous vascularization of the developing mouse sciatic nerve.
For the first time, researchers in this manuscript detail the process of peripheral nerve vascularization in early development, finding that vessels do not invade the nerve space until close to birth. They also show strong links between myelin maturation and vascular health as well as evidence for a novel vessel-guiding molecule in the peripheral nervous system. Overall this paper highlights important biological processes in regards to peripheral nerve development.